Advice for healthcare professionals:
• cases of immune-mediated encephalitis, including anti-N-methyl-D-aspartate (NMDA) receptor encephalitis, have occurred several months after discontinuation of daclizumab• prescribers should contact patients who have discontinued daclizumab and their caregivers and advise them to make contact immediately if any of the common prodromal symptoms or early common neuropsychiatric, behavioural, neurological, cognitive, or movement-related symptoms develop (see description and publications below)• in patients presenting with atypical neuropsychiatric symptoms, a high index of clinical suspicion should be given for autoimmune encephalitis• clinicians are advised to be vigilant for any symptoms suggestive of autoimmune encephalitis; monitoring for encephalitis should continue for 12 months following discontinuation of daclizumab• be aware of a case of Glial fibrillary acidic protein (GFAP)α immunoglobulin G (IgG)-associated encephalitis in a patient being treated with daclizumab recently reported in the literature• if you suspect encephalitis in a patient who has discontinued daclizumab, consider testing for a broad panel of autoantibodies (eg, antigens for neuronal cell surface and synaptic proteins), including anti-NMDA receptor antibody in cerebrospinal fluid (CSF) and serum as early as possible• ensure review of all suspected cases by a specialist in diagnosis and management of autoimmune encephalitis• report suspected adverse drug reactions, including those which occur after the withdrawal of a medicine, to the Yellow Card Scheme without delay